160 related articles for article (PubMed ID: 29359145)
1. Immune Response and Protective Efficacy of a Heterologous DNA-Protein Immunization with
Bayih AG; Daifalla NS; Gedamu L
Biomed Res Int; 2017; 2017():2145386. PubMed ID: 29359145
[TBL] [Abstract][Full Text] [Related]
2. DNA-protein immunization using Leishmania peroxidoxin-1 induces a strong CD4+ T cell response and partially protects mice from cutaneous leishmaniasis: role of fusion murine granulocyte-macrophage colony-stimulating factor DNA adjuvant.
Bayih AG; Daifalla NS; Gedamu L
PLoS Negl Trop Dis; 2014 Dec; 8(12):e3391. PubMed ID: 25500571
[TBL] [Abstract][Full Text] [Related]
3. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection.
Daifalla NS; Bayih AG; Gedamu L
Exp Parasitol; 2012 Jul; 131(3):317-24. PubMed ID: 22580023
[TBL] [Abstract][Full Text] [Related]
4. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
[TBL] [Abstract][Full Text] [Related]
5. Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice.
Mazumder S; Maji M; Das A; Ali N
PLoS One; 2011 Feb; 6(2):e14644. PubMed ID: 21311597
[TBL] [Abstract][Full Text] [Related]
6. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
7. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis.
Stäger S; Smith DF; Kaye PM
J Immunol; 2000 Dec; 165(12):7064-71. PubMed ID: 11120835
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of Leishmania donovani.
Sharma A; Madhubala R
J Immunol; 2009 Dec; 183(12):7719-31. PubMed ID: 19933862
[TBL] [Abstract][Full Text] [Related]
9. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
Mazumdar T; Anam K; Ali N
Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
[TBL] [Abstract][Full Text] [Related]
10. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
Ramos I; Alonso A; Marcen JM; Peris A; Castillo JA; Colmenares M; Larraga V
Vaccine; 2008 Jan; 26(3):333-44. PubMed ID: 18093705
[TBL] [Abstract][Full Text] [Related]
11. Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis.
Tewary P; Saxena S; Madhubala R
Vaccine; 2006 Mar; 24(13):2409-16. PubMed ID: 16413950
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani.
Sukumaran B; Tewary P; Saxena S; Madhubala R
Vaccine; 2003 Mar; 21(11-12):1292-9. PubMed ID: 12559811
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a Leishmania hypothetical protein administered as DNA vaccine or recombinant protein against Leishmania infantum infection and its immunogenicity in humans.
Ribeiro PAF; Dias DS; Lage DP; Costa LE; Martins VT; Tavares GSV; Mendonça DVC; Lima MP; Oliveira JS; Steiner BT; Machado-de-Ávila RA; Roatt BM; Chávez-Fumagalli MA; Menezes-Souza D; Duarte MC; Teixeira AL; Coelho EAF
Cell Immunol; 2018 Sep; 331():67-77. PubMed ID: 29871740
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
Abdian N; Gholami E; Zahedifard F; Safaee N; Rafati S
Exp Parasitol; 2011 Mar; 127(3):627-36. PubMed ID: 21187087
[TBL] [Abstract][Full Text] [Related]
15. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.
Choudhury R; Das P; De T; Chakraborti T
Immunobiology; 2013 Jan; 218(1):114-26. PubMed ID: 22440312
[TBL] [Abstract][Full Text] [Related]
16. A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis.
Tewary P; Jain M; Sahani MH; Saxena S; Madhubala R
J Infect Dis; 2005 Jun; 191(12):2130-7. PubMed ID: 15898000
[TBL] [Abstract][Full Text] [Related]
17. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections.
Ghosh A; Zhang WW; Matlashewski G
Vaccine; 2001 Oct; 20(1-2):59-66. PubMed ID: 11567746
[TBL] [Abstract][Full Text] [Related]
18. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major.
Bhaumik S; Basu R; Sen S; Naskar K; Roy S
Vaccine; 2009 Feb; 27(9):1306-16. PubMed ID: 19162111
[TBL] [Abstract][Full Text] [Related]
19. LmjMAPK10 offers protection against Leishmania donovani infection.
Kumar S; Zutshi S; Patidar A; Bodhale N; Roy S; Sarkar A; Saha B
Parasite Immunol; 2020 Feb; 42(2):e12687. PubMed ID: 31770453
[TBL] [Abstract][Full Text] [Related]
20. The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice.
Iborra S; Soto M; Carrión J; Nieto A; Fernández E; Alonso C; Requena JM
Infect Immun; 2003 Nov; 71(11):6562-72. PubMed ID: 14573678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
